-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Announces Research Collaborators' Abstract Published In Cancer Research Supplement Proceedings On The Use Of Reqorsa Gene Therapy For The Treatment Of Lung Cancer

Benzinga·04/22/2025 12:17:14
Listen to the news

Research Journal Features Genprex Collaborators' Abstract Detailing Positive Preclinical Data on the Use of

Reqorsa® Gene Therapy for the Treatment of Lung Cancer

AUSTIN, Texas, April 22, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators' abstract was published in the online Proceedings supplement of Cancer Research, a scientific journal published by the American Association for Cancer Research (AACR).

 

Genprex collaborators will present the published abstract in a poster presentation at the 2025 AACR Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data from a study of Genprex's lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC)